Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NeoGenomics, Inc. - Common Stock (NQ: NEO )

9.825 +0.305 (+3.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about NeoGenomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Testing & Diagnostics Services Stocks Q4 Recap: Benchmarking Quest (NYSE:DGX)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Quest (NYSE:DGX) and the best and worst... 
Via StockStory
3 Small-Cap Stocks in Hot Water
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
3 Healthcare Stocks Skating on Thin Ice
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
What To Expect From RadNet’s (RDNT) Q4 Earnings
Diagnostic imaging company RadNet (NASDAQ:RDNT) will be reporting results tomorrow after market hours. Here’s what to look for. 
Via StockStory
Demystifying NeoGenomics: Insights From 6 Analyst Reviews
Via Benzinga
5 Analysts Assess NeoGenomics: What You Need To Know
Via Benzinga
Evaluating NeoGenomics: Insights From 4 Financial Analysts
Via Benzinga
Why NeoGenomics (NEO) Shares Are Trading Lower Today
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 21.5% in the afternoon session after the company reported weak fourth-quarter results, with revenue falling below Wall... 
Via StockStory
NeoGenomics (NASDAQ:NEO) Misses Q4 Sales Targets
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) missed Wall Street’s revenue expectations in Q4 CY2024, but sales rose 10.6% year on year to $172 million. On the other hand, the... 
Via StockStory
NeoGenomics (NEO) To Report Earnings Tomorrow: Here Is What To Expect
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting results tomorrow morning. Here’s what to look for. 
Via StockStory
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Many stocks flashed buy signals as the major indexes rose to or above key levels. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Expert Ratings For NeoGenomics
Via Benzinga
Earnings Scheduled For February 18, 2025
Via Benzinga
NEO Stock Earnings: NeoGenomics Beats Revenue for Q2 2024
NEO stock results show that NeoGenomics beat on revenue for the second quarter of 2024. 
Via InvestorPlace
NeoGenomics Earnings Analysis: Q1 Recap
Via Benzinga
NeoGenomics Is On The Upswing, Reversing A CEO-Tied Sell-Off, On Bullish Long-Term Guidance
The company expects sales to grow 12% to 13% annually in the long term. 
Via Investor's Business Daily
NeoGenomics Shares Are Falling Today: What's Going On?
Shares of NeoGenomics, Inc. (NASDAQ: NEO) are, after the company announced that CEO Chris Smith will retire effective April 1 2025. 
Via Benzinga
Shake Shack And Lumen Tech Are Among Top 7 Mid Cap Stocks With Max Gains Last Week (July 28-August 3): Are The Others In Your Portfolio?
Seven mid-cap stocks that performed well last week: LUMN, SHAK, PSN, CWAN, RGEN, FTDR, and NEO. Check if they're in your portfolio! 
Via Benzinga
PayPal Posts Upbeat Earnings, Joins Sprouts Farmers Market, Stanley Black & Decker, Phillips 66 And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Where NeoGenomics Stands With Analysts
Via Benzinga
What 6 Analyst Ratings Have To Say About NeoGenomics
Via Benzinga
Earnings Scheduled For November 14, 2024
Via Benzinga
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
NEO Stock Earnings: NeoGenomics Beats EPS, Beats Revenue for Q1 2024
NEO stock results show that NeoGenomics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Earnings Scheduled For March 15, 2024
Companies Reporting Before The Bell • EHang Holdings (NASDAQ:EH) is expected to report quarterly loss at $0.10 per share on revenue of $7.83 million. 
Via Benzinga
Goldman Sachs Maintains Buy Rating for NeoGenomics: Here's What You Need To Know
Via Benzinga
NeoGenomics Stock Surged But Technicals Point To A Pullback
NeoGenomics stock price popped sharply this week after the company published strong financial results. It soared to a high of $16.50, its highest point since December 29th. It has soared by more than... 
Via Talk Markets
Why International Flavors & Fragrances Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of International Flavors & Fragrances Inc. (NYSE: IFF) fell during Wednesday’s session after the company reported mixed fourth-quarter financial results and reduced its expected quarterly... 
Via Benzinga
Why Is Cancer Genetics Test-Focused NeoGenomics Stock Trading Higher Today?
NeoGenomics shines in Q4 2023 with an EPS turnaround to $0.03, beating estimates. Sales reach $155.55 million. CEO Chris Smith anticipates strong growth, guiding a positive fiscal 2024 outlook with an... 
Via Benzinga
Toll Brothers Posts Upbeat Earnings, Joins Exelon, Garmin, Bausch + Lomb And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Nasdaq Composite falling more than 100 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.